We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Share this :
Print
Genscript PD-L2 Fc Chimera, Human
Genscript PD-L2 Fc Chimera, Human - GSCRPT (Additional S&H or Hazmat Fees May Apply)
List Price
$1,200.00
Your Price
$1,200.00
HOW MUCH YOU SAVE:
0.00 %
NETA PART: | GSCRPT-Z03417-1 |
MFG.PART: | Z03417-1 |
UNSPSC: | 41116127 |
Manufacturer: | GenScript USA Inc |
Product Introduction
Species | Human | ||||
Protein Construction |
| ||||
Purity | > 97% as analyzed by SDS-PAGE | ||||
Endotoxin Level | < 0.2 EU/μg of protein by gel clotting method | ||||
Biological Activity | Immobilized PD-L2, hFc, Human (Cat. No.: Z03417) at 5.0 μg/ml (100 µl/well) can bind Biotin-PD-1 Fc, Human when detected by Streptavidin-HRP. | ||||
Expression System | HEK 293 | ||||
Apparent Molecular Weight | ~75 kDa, on SDS-PAGE under reducing conditions. | ||||
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS, 5% trehalose and mannitol. | ||||
Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O or PBS up to 100 μg/ml. | ||||
Storage & Stability | Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
Background
Target Background | PD-L1 and PD-L2 are ligands for PD-1, a costimulatory molecule that plays an inhibitory role in regulating T cell activation in the periphery. PD-L2 also known as PD-L2, B7-DC serves as a negative and a positive regulator of T cell function. The expression and function of PD-L2 are similar to PD-L1. Both PD-L2−PD-1 and PD-L1−PD-1 signals inhibit T cell proliferation by blocking cell cycle progression but not by increasing cell death. PD-L2−PD-1 interactions are able to inhibit TCR-mediated proliferation and cytokine production in the absence of CD28 costimulation. Threshold for T cell activation may be a balance between activating signals, such as those delivered by the engagement of CD28 by B7-1 and B7-2, and inhibitory signals, mediated by engagement of PD-1 by PD-L1 and PD-L2. The structural conservation of B7-like and CD28-like receptors may reflect the distance between T cells and APCs in the immunological synapse. The PD-L−PD-1 pathway may play a key role in the induction and/or maintenance of peripheral tolerance and autoimmune disease. Because PD-L1 and PD-L2 can inhibit effector T cell proliferation and cytokine production, the PD-L−PD-1 pathway may be an attractive therapeutic target. Blocking the PD-1 pathway may enhance anti-tumor immunity, whereas stimulating this pathway may be useful for down-regulating ongoing immune responses in transplant rejection and autoimmune and allergic diseases. |
Synonyms | B7-DC; bA574F11.2; Btdc; Butyrophilin B7-DC; Butyrophilin-like Protein; CD273 antigen; CD273; CD273PD-1 ligand 2; MGC142240; PD-1-ligand 2; PDCD1L2; MGC142238; PDCD1LG2; PDL2; PD-L2 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
SKU | GSCRPT-Z03417-1 |
---|---|
Supplier Part Number | Z03417-1 |
UM | EA |
UNSPSC | 41116127 |
Manufacturer | GenScript USA Inc |
ProductLine | GSCRPT |
Qty | 1 |
MinOrderQty | 1 |
Weight | 7.00 |
Lead Time | 7 Business Days |
Hazardous | N |